Tyra Biosciences (NASDAQ:TYRA) Stock Price Up 6.5%

Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report)'s stock price shot up 6.5% on Monday . The stock traded as high as $16.78 and last traded at $16.69. 53,973 shares were traded during mid-day trading, a decline of 58% from the average session volume of 129,241 shares. The stock had previously closed at $15.67.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on TYRA. HC Wainwright reiterated a "buy" rating and set a $23.00 target price (up previously from $19.00) on shares of Tyra Biosciences in a research report on Wednesday, March 20th. Wedbush reiterated an "outperform" rating and set a $28.00 price objective on shares of Tyra Biosciences in a report on Thursday, March 21st.

Tyra Biosciences Stock Up 5.0 %

The business has a 50-day moving average price of $17.32 and a two-hundred day moving average price of $14.86. The company has a market capitalization of $863.95 million, a price-to-earnings ratio of -10.22 and a beta of 1.13.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last released its quarterly earnings data on Tuesday, March 19th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.05). On average, sell-side analysts anticipate that Tyra Biosciences, Inc. will post -1.89 EPS for the current fiscal year.

Insider Buying and Selling

In related news, COO Daniel Bensen sold 1,733 shares of the firm's stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $20.09, for a total value of $34,815.97. Following the transaction, the chief operating officer now owns 431,951 shares of the company's stock, valued at approximately $8,677,895.59. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders have sold 15,816 shares of company stock worth $298,165 in the last quarter. Insiders own 15.40% of the company's stock.

Institutional Trading of Tyra Biosciences

Several institutional investors and hedge funds have recently modified their holdings of the stock. Simplex Trading LLC lifted its position in shares of Tyra Biosciences by 198.1% during the third quarter. Simplex Trading LLC now owns 2,009 shares of the company's stock valued at $27,000 after purchasing an additional 1,335 shares in the last quarter. Federated Hermes Inc. lifted its position in shares of Tyra Biosciences by 1,244.2% during the 4th quarter. Federated Hermes Inc. now owns 2,070 shares of the company's stock worth $29,000 after buying an additional 1,916 shares in the last quarter. AJOVista LLC bought a new position in shares of Tyra Biosciences during the 4th quarter worth approximately $59,000. Exchange Traded Concepts LLC boosted its stake in shares of Tyra Biosciences by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 9,531 shares of the company's stock worth $132,000 after buying an additional 2,417 shares during the last quarter. Finally, Corton Capital Inc. bought a new position in shares of Tyra Biosciences in the third quarter valued at approximately $152,000. 84.14% of the stock is owned by hedge funds and other institutional investors.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.